Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

Cited by (1,008)

Items 801–900 of 1,008

1. Molecular Targets of Gemcitabine Action: Rationale for Development of Novel Drugs and Drug Combinations
   Maha Elnaggar, Elisa Giovannetti, Godefridus J. Peters · 2012 · Current Pharmaceutical Design
2. Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer
   Witkiewicz, Agnieszka K., Borja, Nicholas A., Franco, Jorge, Brody, Jonathan R., Yeo, Charles J., Mansour, John, Choti, Michael A., McCue, Peter, Knudsen, Erik S. · 2015 · Oncotarget
3. Role of drug catabolism, modulation of oncogenic signaling and tumor microenvironment in microbe-mediated pancreatic cancer chemoresistance
   Mjriam Capula, Macarena Perán, Geng Xu, Valentina Laura Donati, Dicky Yee, Alessandro Gregori, Yehuda G. Assaraf, Elisa Giovannetti, Dongmei Deng · 2022 · Drug Resistance Updates
4. Treatment of metastatic pancreatic cancer: 25 years of innovation with little progress for patients
   Bishal Gyawali, Christopher M. Booth · 2024 · The Lancet Oncology
5. KRAS: the Achilles’ heel of pancreas cancer biology
   Kristina Drizyte‐Miller, Taiwo Talabi, Ashwin Somasundaram, Adrienne D. Cox, Channing J. Der · 2025 · Journal of Clinical Investigation
6. Erlotinib Has Moderate Single-agent Activity in Chemotherapy-naïve Castration-resistant Prostate Cancer: Final Results of a Phase II Trial
   Chadi Nabhan, Timothy M. Lestingi, Angel G. Galvez, Kathy Tolzien, Susan K. Kelby, Dean Tsarwhas, Steven B. Newman, Jacob David Bitran · 2009 · Urology
7. Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer – a multi-centre randomised phase II study
   Ralf Wilkowski, Stefan Hubert Boeck, S. Ostermaier, Rolf Sauer, M. Herbst, Rainer Fietkau, Michael P. Flentje, S. Miethe, Heinz D Boettcher, Theo Scholten et al. · 2009 · British Journal of Cancer
8. Transcriptomic Analysis Predicts Survival and Sensitivity to Anticancer Drugs of Patients with a Pancreatic Adenocarcinoma
   Pauline Duconseil, Marine Gilabert, Odile Gayet, Céline Loncle, Vincent Moutardier, Olivıer Turrini, Ezequiel Luis Calvo, Jacques Ewald, Marc F. Giovannini, Mohamed Gasmi et al. · 2015 · American Journal Of Pathology
9. Overview of pre-clinical and clinical studies targeting angiogenesis in pancreatic ductal adenocarcinoma
   Kelly E. Craven, Jesse Gore, Murray Korc · 2015 · Cancer Letters
10. A clinical role of staging laparoscopy in patients with radiographically defined locally advanced pancreatic ductal adenocarcinoma
    Sohei Satoi, Hiroaki Yanagimoto, Tomohisa Yamamoto, Hideyoshi Toyokawa, Satoshi Hirooka, So Yamaki, Singh Sapam Opendro, Kentaro Inoue, Taku Michiura, Hironori Ryota et al. · 2015 · World Journal of Surgical Oncology
11. A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanced Pancreatic Cancer
    Sant P. Chawla, Howard W. Bruckner, Michael Andrew Morse, Nupur Assudani, Frederick L. Hall, Erlinda Maria Gordon · 2018 · Molecular Therapy — Oncolytics
12. Rad51/BRCA2 disruptors inhibit homologous recombination and synergize with olaparib in pancreatic cancer cells
    Marinella Roberti, Fabrizio Schipani, Greta Bagnolini, Domenico Milano, Elisa Giacomini, Federico Falchi, Andrea Balboni, Marcella Manerba, Fulvia Farabegoli, Francesca Franco et al. · 2019 · European Journal of Medicinal Chemistry
13. Glycosyltransferase ST6Gal-I promotes the epithelial to mesenchymal transition in pancreatic cancer cells
    Colleen M. Britain, Nikita Bhalerao, Austin D. Silva, Asmi Chakraborty, Donald J. Buchsbaum, Michael R. Crowley, David K. Crossman, Yvonne J. K. Edwards, Susan L. Bellis · 2020 · Journal of Biological Chemistry
14. Targeting signal transduction in pancreatic cancer treatment
    Jen Jen Yeh, Channing J. Der · 2007 · Expert Opinion on Therapeutic Targets
15. Prognostic Factors in Patients with Gemcitabine-Refractory Pancreatic Cancer
    Kohei Nakachi, Junji Furuse, Hiroshi Ishii, Eiichiro Suzuki, Masahiro Yoshino · 2007 · Japanese Journal of Clinical Oncology
16. Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?
    Ursula Maria Vogl, Haleh Andalibi, Alexander Klaus, Laurenz Vormittag, Wolfgang Schima, Bettina Heinrich, Alice Kafka, Thomas Winkler, Leopold Öhler · 2019 · BMC Cancer
17. Pancreatic melatonin enhances anti-tumor immunity in pancreatic adenocarcinoma through regulating tumor-associated neutrophils infiltration and NETosis
    Yau-Tuen Chan, Hor‐Yue Tan, Yuanjun Lu, Cheng Zhang, Chien‐shan Cheng, Junyu Wu, Ning Wang, Yibin Feng · 2023 · Acta Pharmaceutica Sinica B
18. Dose–Volume Analysis of Predictors for Gastrointestinal Toxicity After Concurrent Full-Dose Gemcitabine and Radiotherapy for Locally Advanced Pancreatic Adenocarcinoma
    Jiayi Huang, John M. Robertson, Hong Ye, Jeffrey Margolis, Laura Nadeau, Di Yan · 2011 · International Journal of Radiation Oncology*Biology*Physics
19. Adjuvant and neoadjuvant treatment in pancreatic cancer
    Marta Herreros‐Villanueva · 2012 · World Journal of Gastroenterology
20. Oral Capecitabine in Gemcitabine-Pretreated Patients with Advanced Pancreatic Cancer
    Stefan Hubert Boeck, Ralf Wilkowski, Christiane J. Bruns, Rolf Dieter Issels, Christoph Udo Schulz, Nicolas Moosmann, Dorit Laessig, Michael Haas, Alexander Golf, Volker Heinemann · 2007 · Oncology
21. Erlotinib prolongs survival in pancreatic cancer by blocking gemcitabine-induced MAPK signals.
    K. Miyabayashi, Hideaki Ijichi, Dai Mohri, Motohisa Tada, Keisuke Yamamoto, Yoshinari Asaoka, T. Ikenoue, K. Tateishi, Y. Nakai, H. Isayama et al. · 2013 · Cancer Research
22. Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer
    Soley Bayraktar · 2010 · World Journal of Gastroenterology
23. Minnelide, a novel drug for pancreatic and liver cancer
    Sulagna Banerjee, Ashok Kumar Saluja · 2015 · Pancreatology
24. Phase I Study of Oxaliplatin, Full-Dose Gemcitabine, and Concurrent Radiation Therapy in Pancreatic Cancer
    Sameer P. Desai, Edgar Ben‐Josef, Daniel Paul Normolle, Isaac R. Francis, Joel K. Greenson, Diane M. Simeone, Alfred E. Chang, Lisa M. Colletti, Theodore Steven Lawrence, Mark M. Zalupski · 2007 · Journal of Clinical Oncology
25. Clinical Characteristics of Adenosquamous Carcinoma of the Pancreas
    Hiroshi Imaoka, Yasuhiro Shimizu, Nobumasa Mizuno, Kazuo Hara, Susumu Hijioka, Masahiro Tajika, Shinya Kondo, Tsutomu Tanaka, Takeshi Ogura, Tomohiko Obayashi et al. · 2014 · Pancreas
26. Clinical Significance of Glucose to Lymphocyte Ratio (GLR) as a Prognostic Marker for Patients With Pancreatic Cancer
    Ailing Zhong, Chien‐shan Cheng, Jinyan Kai, Renquan Lu, Lin Guo · 2020 · Frontiers in Oncology
27. Differentiation Therapy Targeting the β-Catenin/CBP Interaction in Pancreatic Cancer
    Manegold, Philipp, Lai, Keane, Wu, Yongfeng, Teo, Jia-Ling, Lenz, Heinz-Josef, Genyk, Yuri, Pandol, Stephen, Wu, Kaijin, Lin, David, Chen, Yibu et al. · 2018 · Cancers
28. Toll-like Receptor 9 Agonist IMO Cooperates with Cetuximab in K - Ras Mutant Colorectal and Pancreatic Cancers
    Rosa, Roberta, Melisi, Davide, Damiano, Vincenzo, Bianco, Roberto, Garofalo, Sonia, Gelardi, Teresa, Agrawal, Sudhir, Di Nicolantonio, Federica, Scarpa, Aldo, Bardelli, Alberto et al. · 2011 · Clinical Cancer Research
29. Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma
    Xi Wang, Chengsheng Zhang, Xuyuan Dong, Yuan Hu, Baojun Duan, Jun Bai, Yinying Wu, Lin Fan, Xin-Hua Liao, Ye Kang et al. · 2022 · World Journal of Gastrointestinal Oncology
30. Targeting EGF-receptor(s) - STAT1 axis attenuates tumor growth and metastasis through downregulation of MUC4 mucin in human pancreatic cancer
    Parthasarathy Seshacharyulu, Moorthy Palanimuthu Ponnusamy, Satyanarayana Rachagani, Imayavaramban Lakshmanan, Dhanya Haridas, Ying Yan, Apar Kishor Ganti, Surinder K. Batra · 2014 · Oncotarget
31. Epidermal growth factor receptor in adrenocortical tumors: analysis of gene sequence, protein expression and correlation with clinical outcome
    Patrick Adam, Stefanie Hahner, Martina Hartmann, Barbara Heinrich, Marcus O. Quinkler, Holger Sven Willenberg, Wolfgang Saeger, Silviu Sbiera, Sebastian Schmull, Hans-Ullrich Voelker et al. · 2010 · Modern Pathology
32. Small tyrosine kinase inhibitors interrupt EGFR signaling by interacting with erbB3 and erbB4 in glioblastoma cell lines
    Estefanía Carrasco‐García, Miguel Saceda, Silvina Grasso, Lourdes Rocamora‐Reverte, Mariano Conde, Ángeles Gómez‐Martínez, Pilar García-Morales, José A. Ferragut, Isabel Martínez-Lacaci · 2011 · Experimental Cell Research
33. Bufalin exerts antitumor effects by inducing cell cycle arrest and triggering apoptosis in pancreatic cancer cells
    Meiying Li, Xuejun Yu, Hui Guo, Limei Sun, Aijun Wang, Qiji Liu, Xiuwen Wang, Jisheng Li · 2013 · Tumor Biology
34. Phase I Study of Rigosertib, an Inhibitor of the Phosphatidylinositol 3-Kinase and Polo-like Kinase 1 Pathways, Combined with Gemcitabine in Patients with Solid Tumors and Pancreatic Cancer
    Wen Wee Ma, Wells A. Messersmith, Grace Kho Dy, Colin D. Weekes, Amy Whitworth, Chen Ren, Manoj L. Maniar, Francois E. Wilhelm, Sabine Eckhardt, Alex A. Adjei et al. · 2012 · Clinical Cancer Research
35. Overexpression of Tumor Vascular Endothelial Growth Factor A May Portend an Increased Likelihood of Progression in a Phase II Trial of Bevacizumab and Erlotinib in Resistant Ovarian Cancer
    Setsuko K. Chambers, Mary C. Clouser, Amanda F. Baker, Denise J. Roe, Haiyan Cui, MOLLY A. BREWER, Kenneth D. Hatch, Michael S. Gordon, Mike F. Janicek, Jeffrey D. Isaacs et al. · 2010 · Clinical Cancer Research
36. Epidermal growth factor receptor (EGFR)—MAPK—nuclear factor(NF)‐κB—IL8: A possible mechanism of particulate matter(PM) 2.5‐induced lung toxicity
    Seung-Chan Jeong, Yoon Cho, Mi‐Kyung Song, Eunil Lee, Jae‐Chun Ryu · 2017 · Environmental Toxicology
37. Current status on the place of FOLFIRINOX in metastatic pancreatic cancer and future directions
    Aurélien Lambert, Céline Gavoille, Thierry Conroy · 2017 · Therapeutic Advances in Gastroenterology
38. Cyclooxygenase‐2 in gastrointestinal malignancies
    Ganji Purnachandra Nagaraju, Bassel F. El‐Rayes · 2019 · Cancer
39. Comparison of efficacy and safety between standard-dose and modified-dose FOLFIRINOX as a first-line treatment of pancreatic cancer
    Huapyong Kang, Jung Hyun Jo, Hee Seung Lee, Moon Jae Chung, Seungmin Bang, Seung Woo Park, Si Young Song, Jeong Youp Park · 2018 · World Journal of Gastrointestinal Oncology
40. Pre-clinical Models of Metastasis in Pancreatic Cancer
    Miquel, Maria, Zhang, Shuman, Pilarsky, Christian · 2021 · Frontiers in Cell and Developmental Biology
41. Functional roles of SRC signaling in pancreatic cancer: Recent insights provide novel therapeutic opportunities
    Ashleigh R. Poh, Matthias Ernst · 2023 · Oncogene
42. Treatment of locally advanced unresectable pancreatic cancer: a 10-year experience.
    Nadia Karen Malik, Kilian Salerno May, Rameela Chandrasekhar, Wen Wee Ma, L. Flaherty, Renuka V. Iyer, John F. Gibbs, Boris W. Kuvshinoff, Gregory E. Wilding, Graham Walter Warren et al. · 2012 · PubMed Central
43. Glycogen synthase kinase 3β inhibition sensitizes pancreatic cancer cells to gemcitabine
    Takeo Shimasaki, Yasuhito Ishigaki, Yuka Nakamura, Takanobu Takata, Naoki Nakaya, Hideo Nakajima, Itaru Sato, Xia Zhao, Ayako Kitano, Kazuyuki Kawakami et al. · 2011 · Journal of Gastroenterology
44. Regional Intra-Arterial vs. Systemic Chemotherapy for Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Fenghua Liu, Yong Tang, Junwei Sun, Zhanna Yuan, Shasha Li, Jun Sheng, He Ren, Jihui Hao · 2012 · PLoS ONE
45. Pancreatic cancer: diagnosis and treatments
    Hongyu Li, Zhong-Min Cui, Chen Jiang, Xiaozhong Guo, Yingyi Li · 2015 · Tumor Biology
46. A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer
    Daniel John Renouf, Malcolm J. Moore, David William Hedley, Sharlene Gill, Derek J. Jonker, Eric Xueyu Chen, David Walde, Rakesh Goel, Bernadette Southwood, Isabelle C Gauthier et al. · 2010 · Investigational New Drugs
47. Stroma and pancreatic ductal adenocarcinoma: An interaction loop
    Guopei Luo, Jiang Long, Bo Zhang, Chen Liu, Jin Xu, Quanxing Ni, Xianjun Yu · 2012 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
48. FKBP5 as a Selection Biomarker for Gemcitabine and Akt Inhibitors in Treatment of Pancreatic Cancer
    Junmei Hou, Liewei Wang · 2012 · PLoS ONE
49. Molecular targeted therapies for pancreatic cancer
    Daniel Borja–Cacho, Eric Hans Jensen, Ashok Kumar Saluja, Donald J. Buchsbaum, Selwyn Maurice Vickers · 2008 · The American Journal of Surgery
50. Histone deacetylase inhibitors and pancreatic cancer: Are there any promising clinical trials?
    Ioannis S. Koutsounas · 2013 · World Journal of Gastroenterology
51. Folliculitis Induced by EGFR Inhibitors, Preventive and Curative Efficacy of Tetracyclines in the Management and Incidence Rates According to the Type of EGFR Inhibitor Administered: A Systematic Literature Review
    Jean‐Baptiste Bachet, L. Peuvrel, Claude Bachmeyer, Z. Reguiaï, Pierre‐Antoine Gourraud, Olivier Bouché, Marc Ychou, René‐Jean Bensadoun, Brigitte Dréno, Thierry André · 2012 · The Oncologist
52. Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer
    Jessica D. Sun, Qian Liu, Dharmendra Ahluwalia, Wen‐Wu Li, Fanying Meng, Yan Wang, Deepthi Bhupathi, Ayesha S. Ruprell, Charles P. Hart · 2015 · Cancer Biology & Therapy
53. Therapeutic potential of novel selective-spectrum kinase inhibitors in oncology
    Patricia Mucci LoRusso, Joseph P. Eder · 2008 · Expert Opinion on Investigational Drugs
54. Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts
    Christel Larbouret, Bruno Robert, Caroline Mollévi, Frederique Madeleine Penault-Llorca, Alexandre Ho-Pun-Cheung, Sébastien Morisseau, Isabelle Navarro‐Teulon, Jean Pierre Mach, André Pèlegrin, D. Azria · 2009 · Annals of Oncology
55. Volume matters in the systemic treatment of metastatic pancreatic cancer: a population-based study in the Netherlands
    Nadia Haj Mohammad, Nienke Bernards, Marc G. Besselink, Olivier R. Busch, Johanna W. Wilmink, G. J. M. Creemers, Ignace H. J. T. de Hingh, V.E.P.P. Lemmens, Hanneke W.M. van Laarhoven · 2016 · Journal of Cancer Research and Clinical Oncology
56. Prognostic Factors for Risk Stratification of Patients with Recurrent or Metastatic Pancreatic Adenocarcinoma Who Were Treated with Gemcitabine-Based Chemotherapy
    Inkeun Park, Seung Joon Choi, Young Saing Kim, Hee Kyung Ahn, Junshik Hong, Sun Jin Sym, Jinny Park, Eun Kyung Cho, Jae Hoon Lee, Yong Ju Shin et al. · 2016 · Cancer Research and Treatment
57. Gemcitabine mono-therapy versus gemcitabine plus targeted therapy in advanced pancreatic cancer: a meta-analysis of randomized phase III trials
    Alessandro Ottaiano, Monica Capozzi, Chiara De Divitiis, Alfonso De Stefano, Gerardo Botti, Antonio Avallone, Salvatore Tafuto · 2017 · Acta Oncologica
58. Profiling tumour heterogeneity through circulating tumour DNA in patients with pancreatic cancer
    Patricia Adamo, Caroline M. Cowley, Christopher P. Neal, Vilas Mistry, Karen Page, Ashley Robert Dennison, John Isherwood, Robert K. Hastings, Jinli Luo, David Allan Moore et al. · 2017 · Oncotarget
59. New Developments in the Molecular Mechanisms of Pancreatic Tumorigenesis
    Matthäus Felsenstein, Ralph H. Hruban, Laura DeLong Wood · 2017 · Advances in Anatomic Pathology
60. Targeting the complexity of Src signalling in the tumour microenvironment of pancreatic cancer: from mechanism to therapy
    Ashleigh Parkin, Jennifer Man, Paul Timpson, Marina Pajic · 2019 · FEBS Journal
61. The Basic Helix-Loop-Helix Transcription Factor E47 Reprograms Human Pancreatic Cancer Cells to a Quiescent Acinar State With Reduced Tumorigenic Potential
    Kim, SangWun, Lahmy, Reyhaneh, Riha, Chelsea, Yang, Challeng, Jakubison, Brad L., van Niekerk, Jaco, Staub, Claudio, Wu, Yifan, Gates, Keith, Dong, Duc Si et al. · 2015 · Pancreas
62. Molecular Mechanisms Underlying the Role of MicroRNAs in the Chemoresistance of Pancreatic Cancer
    Ingrid Garajová, Tessa Y. S. Le Large, Adam Enver Frampton, Christian D. Rolfo, Johannes Voortman, Elisa Giovannetti · 2014 · BioMed Research International
63. Inhibitors of the Cancer Target Ribonucleotide Reductase, Past and Present
    Sarah E. Huff, Jordan Michael Winter, Chris Godfrey Dealwis · 2022 · Biomolecules
64. Cardiovascular Toxicities Associated with Tyrosine Kinase Inhibitors
    Nicolas Sayegh, Juliet Yirerong, Neeraj Agarwal, Daniel Addison, Michael G. Fradley, Jörge E. Cortes, Neal L. Weintraub, Nazish Sayed, Girindra Ghanshyam Raval, Avirup Guha · 2023 · Current Cardiology Reports
65. Current and Emerging Treatment Options for Pancreatic Cancer: A Comprehensive Review
    Umar Hayat, Phillip Croce, Aseel Saadeh, Karna Desai, John Appiah, Sidrah Khan, Yakub Iqbal Khan, Kishore Kumar, Ahmad Hanif · 2025 · Journal of Clinical Medicine
66. Gemcitabine in elderly patients with advanced pancreatic cancer
    Olivia Hentic · 2011 · World Journal of Gastroenterology
67. Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis
    Linda S. Elting, Yu-Chia Chang, Pratibha Parelkar, Christine Bettine Boers-Doets, Marisol Michelet, Angel Guido Hita, Tanya Rouleau, Catherine D. Cooksley, Josiah K. Halm, Madhuri V. Vithala et al. · 2013 · Supportive Care in Cancer
68. Dermatologic Toxicities from Monoclonal Antibodies and Tyrosine Kinase Inhibitors against EGFR: Pathophysiology and Management
    Shaad Essa Abdullah, Missak Haigentz, Bilal Piperdi · 2012 · Chemotherapy Research and Practice
69. Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer
    Takuji Okusaka, Junji Furuse, Akihiro Funakoshi, Tatsuya Ioka, Kenji Yamao, Shinichi Ohkawa, Narikazu Boku, Yoshito Komatsu, Shoji Nakamori, Haruo Iguchi et al. · 2010 · Cancer Science
70. A novel 3-dimensional culture system uncovers growth stimulatory actions by TGFβ in pancreatic cancer cells
    Lorenzo F. Sempere, Jason R. Gunn, Murray Korc · 2011 · Cancer Biology & Therapy
71. A PK2/Bv8/PROK2 Antagonist Suppresses Tumorigenic Processes by Inhibiting Angiogenesis in Glioma and Blocking Myeloid Cell Infiltration in Pancreatic Cancer
    Valerie F. Curtis, Hui Wang, Pengyuan Yang, Roger E. McLendon, Xiaohan Li, Qun‐Yong Zhou, Xiao‐Fan Wang · 2013 · PLoS ONE
72. A phase II study of a personalized peptide vaccination for chemotherapy-resistant advanced pancreatic cancer patients
    Shigeru Yutani, Nobukazu Komatsu, Munehiro Yoshitomi, Satoko Matsueda, Koji Yonemoto, Takashi Mine, Masanori Noguchi, Yuki Ishihara, Akira Yamada, Kyogo Itoh et al. · 2013 · Oncology Reports
73. Molecular Profiling of Direct Xenograft Tumors Established from Human Pancreatic Adenocarcinoma After Neoadjuvant Therapy
    Michael P. Kim, Mark Joseph Truty, Woonyoung Choi, Ya’an Kang, Xavier Chopin‐Laly, Gary E. Gallick, Huamin Wang, David James McConkey, Rosa F. Hwang, Craig D. Logsdon et al. · 2011 · Annals of Surgical Oncology
74. Metronomic Gemcitabine in Combination with Sunitinib Inhibits Multisite Metastasis and Increases Survival in an Orthotopic Model of Pancreatic Cancer
    Hop S. Tran Cao, Michael Bouvet, Sharmeela Kaushal, Alex M. Keleman, Eric Romney, Ginna Kim, John P. Fruehauf, David K. Imagawa, Robert M. Hoffman, Matthew H. G. Katz · 2010 · Molecular Cancer Therapeutics
75. Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer
    Michael Haas, Rüdiger Paul Laubender, P Stieber, Stefan Holdenrieder, Christiane J. Bruns, Ralf Wilkowski, Ulrich Mansmann, Volker Heinemann, Stefan Hubert Boeck · 2010 · Tumor Biology
76. Adverse kidney effects of epidermal growth factor receptor inhibitors
    Hassan Izzedine, Mark Anthony Perazella · 2017 · Nephrology Dialysis Transplantation
77. Functions of pancreatic stellate cell-derived soluble factors in the microenvironment of pancreatic ductal carcinoma
    Qi Wu, Ying Tian, Jingqiu Zhang, Hongpeng Zhang, Fengming Gu, Yongdie Lu, Shengnan Zou, Yuji Chen, Pengxiang Sun, Mengyue Xu et al. · 2017 · Oncotarget
78. Management of Borderline Resectable Pancreatic Cancer
    Diego A.S. Toesca, Amanda Jeanette Koong, George A. Poultsides, Brendan Christopher Visser, Sigurdís Haraldsdóttir, Albert C. Koong, Daniel Tandel Chang · 2018 · International Journal of Radiation Oncology*Biology*Physics
79. HIFU is safe, effective, and feasible in pancreatic cancer patients: a monocentric retrospective study among 523 patients
    Zhouyu Ning, Jing Xie, Qiwen Chen, Chenyue Zhang, Litao Xu, Libin Song, Zhiqiang Meng · 2019 · OncoTargets and Therapy
80. Pharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
    Antonio Jimeno, Manuel M. Hidalgo · 2006 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
81. Markers involved in resistance to cytotoxics and targeted therapeutics in pancreatic cancer
    Ghassan El Maalouf, Christophe Le Tourneau, George N. Batty, Sandrine J. Faivre, Éric Raymond · 2008 · Cancer Treatment Reviews
82. Combination Therapies and Drug Delivery Platforms in Combating Pancreatic Cancer
    Lei, Fan, Xi, Xinyuan, Batra, Surinder K., Bronich, Tatiana K. · 2019 · The Journal of Pharmacology and Experimental Therapeutics
83. A Retrospective Analysis of VeriStrat Status on Outcome of a Randomized Phase II Trial of First-Line Therapy with Gemcitabine, Erlotinib, or the Combination in Elderly Patients (Age 70 Years or Older) with Stage IIIB/IV Non–Small-Cell Lung Cancer
    Thomas E. Stinchcombe, Joanna Roder, Amy H. Peterman, Julia Grigorieva, Carrie B. Lee, Dominic T. Moore, Mark A. Socinski · 2013 · Journal of Thoracic Oncology
84. Advances in the treatment of pancreatic cancer: Limitations of surgery and evaluation of new therapeutic strategies
    Yukihiro Yokoyama, Yuji Nimura, Masato Nagino · 2009 · Surgery Today
85. Novel advances in pancreatic cancer treatment
    Michel Vulfovich, Caio S. Rocha-Lima · 2008 · Expert Review of Anticancer Therapy
86. Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study
    Stefano Cascinu, Rossana Berardi, Alberto F. Sobrero, Paolo Bidoli, Roberto Labianca, Salvatore Siena, Daris Ferrari, Sandro Barni, Enrico Aitini, Vittorina Zagonel et al. · 2013 · Digestive and Liver Disease
87. Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models
    Kuichun Zhu, Hong Qin, Soung-chul Cha, Sattva Swarup Neelapu, Willem W. Overwijk, Gregory A. Lizee, James L. Abbruzzese, Patrick Hwu, Laszlo George Radvanyi, Larry W. Kwak et al. · 2007 · Vaccine
88. A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2
    Yousuke Nakai, Hiroyuki Isayama, Hideaki Ijichi, Takashi Sasaki, Naminatsu Takahara, Yukiko Ito, Saburo Matsubara, Rie Uchino, Hiroshi Yagioka, Toshihiko Arizumi et al. · 2013 · Investigational New Drugs
89. Inhibition of pancreatic carcinoma by homo- and heterocombinations of antibodies against EGF-receptor and its kin HER2/ErbB-2
    Ruth Maron, Bilha Schechter, Maicol Mancini, Georg Mahlknecht, Yosef Yarden, Michael Sela · 2013 · Proceedings of the National Academy of Sciences
90. Fool’s gold, lost treasures, and the randomized clinical trial
    David J. Stewart, Razelle Kurzrock · 2013 · BMC Cancer
91. FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts
    Cindy Neuzillet · 2012 · World Journal of Gastroenterology
92. Combining EGFR and mTOR Blockade for the Treatment of Epithelioid Sarcoma
    Xianbiao Xie, Markus P. Ghadimi, Eric D. Young, Roman Belousov, Quan-Sheng Zhu, Juehui Liu, Gonzalo Lopez, Chiara Colombo, Tingsheng Peng, David Reynoso et al. · 2011 · Clinical Cancer Research
93. Predictive factors of solid food intake in patients with malignant gastric outlet obstruction receiving self‐expandable metallic stents for palliation
    Takashi Sasaki, Hiroyuki Isayama, Yousuke Nakai, Osamu Togawa, Hirofumi Kogure, Kazumichi Kawakubo, Suguru Mizuno, Yoko Yashima, Yukiko Ito, Natsuyo Yamamoto et al. · 2011 · Digestive Endoscopy
94. Phase I Study of Oral Gemcitabine Prodrug (LY2334737) Alone and in Combination with Erlotinib in Patients with Advanced Solid Tumors
    Stijn L.W. Koolen, Petronella Oda Witteveen, Robert S. Jansen, Marlies H.G. Langenberg, Roelien H. Kronemeijer, Annemarie Nol, Ignacio Garcia‐Ribas, Sophie Callies, Karim Adnane Benhadji, Christopher A. Slapak et al. · 2011 · Clinical Cancer Research
95. SPARC-Independent Delivery of Nab -Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts
    Harrison Kim, Sharon L. Samuel, Pedro Pablo Lopez-Casas, William E. Grizzle, Manuel M. Hidalgo, Joy L. Kovar, Denise K. Oelschlager, Kurt R. Zinn, Jason M. Warram, Donald J. Buchsbaum · 2016 · Molecular Cancer Therapeutics
96. A Phase II Trial of Erlotinib as Maintenance Treatment After Gemcitabine Plus Platinum-based Chemotherapy in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma
    Benoît You, Christophe Le Tourneau, Eric Xueyu Chen, Lisa E. Wang, Andrea Jarvi, Rikki R. Bharadwaj, Suzanne Kamel‐Reid, Bayardo Perez‐Ordoñez, Vijay Mann, Lillian L. Siu · 2011 · American Journal of Clinical Oncology
97. Pretreatment C-reactive protein to albumin ratio for predicting overall survival in advanced pancreatic cancer patients
    Junjie Hang, Peng Xue, Haiyan Yang, Shaobo Li, Donghui Chen, Lifei Zhu, Weiyi Huang, Shujuan Ren, Yue Zhu, Liwei Wang · 2017 · Scientific Reports
98. HB-EGF–EGFR Signaling in Bone Marrow Endothelial Cells Mediates Angiogenesis Associated with Multiple Myeloma
    Luigia Rao, Donato Giannico, Patrizia Leone, Antonio Giovanni Solimando, Eugenio Maiorano, Concetta Caporusso, Loren Duda, Roberto Tamma, Rosanna Mallamaci, Nicola Susca et al. · 2020 · Cancers
99. Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe
    Muhammad Ahsan Javed, Georg Beyer, Nha Ngoc Hoa Le, Alessio Vinci, Helen H. Wong, Daniel H. Palmer, Robert David Morgan, Ángela Lamarca, Richard A Hubner, Juan W. Valle et al. · 2018 · Pancreatology
100. Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival
     Benjamin M. Ellingson, Patrick Yung Wen, Susan Marina Chang, Martin J. van den Bent, Michael A. Vogelbaum, Gang Li, Shanpeng J. Li, Jiyoon Kim, Gilbert Youssef, Wolfgang Wick et al. · 2023 · Neuro-Oncology